Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Cirugía y cirujanos
versión On-line ISSN 2444-054Xversión impresa ISSN 0009-7411
Resumen
ATES, Caglayan; DILBAZ, Berna; ERGANI, Seval Yılmaz y ATABAY, Fuad. The effect of antiangiogenic agent aflibercept on surgically induced endometriosis in a rat model. Cir. cir. [online]. 2024, vol.92, n.1, pp.10-19. Epub 07-Mayo-2024. ISSN 2444-054X. https://doi.org/10.24875/ciru.23000072.
Objective:
The aim of the study is to show for the first time how aflibercept affects endometriosis lesions.
Material and methods:
Surgically induced endometriosis in Wistar albino female rats. Rats with endometriosis were randomly divided into three groups: control (Co), aflibercept (Af), and leuprolide acetate (Le). Then, Af, aflibercept, and Le received leuprolide acetate. The control group was not treated. The weights and changes in intra-abdominal adhesions of the rats before and after treatment were recorded according to the Blauer adhesion score. Blood extracted for sacrifice was analyzed. Endometriotic lesions were evaluated for size, volume, histology, and immunohistochemistry (vascular endothelial growth factor [VEGF] and CD31). Significance level was accepted as p < 0.05.
Results:
Aflibercept significantly reduced endometrial implant volume (p = 0.002). The explant epithelial histological score showed a significant difference between aflibercept and leuprolide acetate (p = 0.006) and between aflibercept and control groups (p = 0.002). Aflibercept decreased VEGF-H and CD31 expression (p = 0.001) more than leuprolide acetate. Aflibercept improved adhesions (p = 0.006).
Conclusion:
Aflibercept is more successful than leuprolide acetate in the treatment of endometriosis.
Palabras llave : Aflibercept; Leuprolide acetate; Angiogenesis; Endometriosis; Vascular endothelial growth factor.